Leone Patterson is serving as Adverum’s chief executive officer and director. She is also serving as the Company’s current chief financial officer and joined Adverum in June 2016. Ms. Patterson has 20 years of experience in the biotechnology industry. Previously, Ms. Patterson served as the chief financial officer of Diadexus, Inc. Earlier, Ms. Patterson was vice president and chief financial officer of Transcept Pharmaceuticals, Inc. until it was acquired by Paratek Pharmaceuticals Inc. Previously, Ms. Patterson served as vice president and global corporate controller of NetApp, Inc. In addition, Ms. Patterson was vice president of finance at Exelixis, Inc. Earlier in her career, Ms. Patterson worked at Novartis AG as vice president of global business planning and analysis after working at Chiron, which was acquired by Novartis AG. Ms. Patterson began her career at KPMG working in the firm’s audit practice. Ms. Patterson earned a B.S. in Business Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
We are a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases.
Leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. We are well positioned with core capabilities, which include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients.
At Adverum, our values underscore our business and shape how we think of the patients we hope to help, how we apply science to medicine, and how we work and grow as a company.